The scientist’s investigation covers issues in Internal medicine, Endocrinology, Type 2 diabetes, Diabetes mellitus and Immunology. His Internal medicine research includes themes of Downregulation and upregulation and Surgery. His work carried out in the field of Endocrinology brings together such families of science as Apoptosis and Programmed cell death.
As part of the same scientific family, Marc Y. Donath usually focuses on Type 2 diabetes, concentrating on Autoimmunity and intersecting with Pancreatic hormone. His research investigates the link between Diabetes mellitus and topics such as Interleukin 1 receptor antagonist that cross with problems in Glycated hemoglobin, Glucose tolerance test, Intention-to-treat analysis and Anakinra. His Immunology research is multidisciplinary, incorporating perspectives in MEDLINE and Bioinformatics.
His primary scientific interests are in Internal medicine, Endocrinology, Type 2 diabetes, Diabetes mellitus and Insulin. His study ties his expertise on Gastroenterology together with the subject of Internal medicine. As a part of the same scientific study, Marc Y. Donath usually deals with the Endocrinology, concentrating on Apoptosis and frequently concerns with Cell biology.
His Type 2 diabetes study incorporates themes from Cell, Interleukin 1 receptor antagonist, Obesity and Inflammation, Immunology. His study connects Adverse effect and Diabetes mellitus. His Insulin research is multidisciplinary, incorporating elements of Paracrine signalling, Glucagon-like peptide-1 and Postprandial Hypoglycemia.
His primary areas of investigation include Internal medicine, Endocrinology, Type 2 diabetes, Diabetes mellitus and Anakinra. He works mostly in the field of Internal medicine, limiting it down to topics relating to Gastroenterology and, in certain cases, Insulin secretion and Hypoparathyroidism, as a part of the same area of interest. His Endocrinology research incorporates themes from Receptor and Placenta.
His Type 2 diabetes research incorporates elements of Cancer research, Inflammation, Beta, Insulin resistance and Antibody. His biological study spans a wide range of topics, including Retrospective cohort study, Immunology and Pharmacology. His studies in Anakinra integrate themes in fields like Empagliflozin and Receptor antagonist.
His main research concerns Internal medicine, Type 2 diabetes, Tocilizumab, Diabetes mellitus and Endocrinology. With his scientific publications, his incorporates both Internal medicine and Crossover study. The Type 2 diabetes study combines topics in areas such as Inflammation and Pathogenesis.
His studies deal with areas such as Sitagliptin, Glucagon-like peptide-1, Pharmacology and Glucose homeostasis as well as Tocilizumab. His work carried out in the field of Diabetes mellitus brings together such families of science as Innate immune system, Disease, Immunology and Immunity. The concepts of his Endocrinology study are interwoven with issues in Interleukin, Interleukin 1 receptor antagonist and Antagonism.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Type 2 diabetes as an inflammatory disease.
Marc Y. Donath;Steven E. Shoelson.
Nature Reviews Immunology (2011)
Interleukin-1-receptor antagonist in type 2 diabetes mellitus.
Claus M Larsen;Mirjam Faulenbach;Allan Vaag;Allan Vaag;Aage Vølund.
The New England Journal of Medicine (2007)
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Kathrin Maedler;Pavel Sergeev;Frédéric Ris;José Oberholzer.
Journal of Clinical Investigation (2002)
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Paul M Ridker;Jean G MacFadyen;Tom Thuren;Brendan M Everett.
The Lancet (2017)
Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells
Helga Ellingsgaard;Irina Hauselmann;Beat Schuler;Abdella M Habib.
Nature Medicine (2011)
Increased Number of Islet-Associated Macrophages in Type 2 Diabetes
Jan A. Ehses;Aurel Perren;Elisabeth Eppler;Pascale Ribaux.
Diabetes (2007)
Distinct Effects of Saturated and Monounsaturated Fatty Acids on β-Cell Turnover and Function
K. Maedler;G.A. Spinas;D. Dyntar;W. Moritz.
Diabetes (2001)
Monounsaturated Fatty Acids Prevent the Deleterious Effects of Palmitate and High Glucose on Human Pancreatic β-Cell Turnover and Function
Kathrin Maedler;José Oberholzer;Pascal Alain Robert Bucher;Giatgen A Spinas.
Diabetes (2003)
Targeting inflammation in the treatment of type 2 diabetes: time to start
Marc Y. Donath.
Nature Reviews Drug Discovery (2014)
Inflammatory mediators and islet β-cell failure: a link between type 1 and type 2 diabetes
Marc Y. Donath;Joachim Størling;Kathrin Maedler;Thomas Mandrup-Poulsen;Thomas Mandrup-Poulsen.
Journal of Molecular Medicine (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Copenhagen
University of Geneva
University Hospital of Basel
University of Lille
University of Basel
University of Colorado Denver
Steno Diabetes Center
University of Zurich
Radboud University Nijmegen
University of Bonn
University of Alberta
Vrije Universiteit Amsterdam
United States Census Bureau
National and Kapodistrian University of Athens
Michigan State University
Georgia Institute of Technology
University of Leeds
Nanyang Technological University
Kyoto University
Spanish National Research Council
Autonomous University of Barcelona
Charité - University Medicine Berlin
University of California, San Francisco
University of Turin
University of Oslo
Oregon Research Institute